Klaus G Parhofer
Overview
Explore the profile of Klaus G Parhofer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
214
Citations
4796
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Parhofer K, Aguiar C, Banach M, Drexel H, Gouni-Berthold I, de Isla L, et al.
Eur Heart J Cardiovasc Pharmacother
. 2025 Mar;
PMID: 40052330
The clinically important link between low-density lipoprotein cholesterol (LDL-C) lowering and cardiovascular (CV) risk reduction is well-established and reflected in the 2019 European Society of Cardiology/European Atherosclerosis Society guidelines for...
2.
Welty F, Parhofer K, Konstam M, Palmer M, Greenberg B, Daher R, et al.
Ther Innov Regul Sci
. 2025 Feb;
PMID: 40011379
In November 2007, a black box warning was mandated for rosiglitazone in type 2 diabetes mellitus (T2DM) based on an increased risk of ischemic cardiovascular (CV) events. The Food and...
3.
4.
Parhofer K, Bramlage P, Gries C, Harder C, Look C, Paar W, et al.
Drugs Real World Outcomes
. 2025 Jan;
12(1):63-74.
PMID: 39875772
Background: Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 used for the reduction of low-density lipoprotein cholesterol (LDL-C) in high-risk patients not reaching their...
5.
Gernert J, Christmann T, Kaufmann E, Delazer L, Kirsch I, Levin J, et al.
Ophthalmology
. 2024 Dec;
PMID: 39675637
Purpose: Peripapillary hyperreflective ovoid mass-like structures (PHOMSs) have been identified in ophthalmic and neurologic diseases. Because PHOMSs were found more frequently in these cohorts compared with healthy control participants, it...
6.
7.
Toth P, Chapman M, Parhofer K, Nelson J
Am Heart J Plus
. 2024 Apr;
17:100148.
PMID: 38559888
None of the clinical trials of omega-3 fatty acids using combinations of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) were able to show any effect on cardiovascular outcomes, despite reductions...
8.
9.
10.